GlassScriptPhysician profile
Omayra Sanchez
NPI 1871339762
$1,990.21
in general payments reported to CMS, 2019-2025
17 companies · $1,749 in 2025
The $1,749 reported for 2025 was more than what 92% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $241 · 2025: $1,749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,905 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,905.22 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fennec Pharmaceuticals, INC. | $482.50 | 2025 | Fyarro |
| Genmab U.S., INC. | $262.47 | 2024-2025 | Tivdak |
| Caris Mpi, INC. | $196.85 | 2025 | Mi Cancer Seek |
| Coherus Oncology, INC. | $190.38 | 2024-2025 | Loqtorzi |
| Merck Sharp & Dohme LLC | $172.89 | 2024-2025 | Keytruda, Keytruda Qlex |
| Bayer Healthcare Pharmaceuticals INC. | $166.77 | 2025 | |
| Novartis Pharmaceuticals Corporation | $96.23 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $84.99 | 2025 | Lynparza |
| Glaxosmithkline, LLC. | $76.50 | 2025 | Jemperli |
| Janssen Biotech, INC. | $74.44 | 2025 | Darzalex, Tecvayli, Talvey |
| Stemline Therapeutics INC. | $53.99 | 2025 | Orserdu |
| Pfizer INC. | $27.86 | 2025 | |
| Daiichi Sankyo INC. | $27.76 | 2025 | Injectafer |
| Pharmaessentia USA Corporation | $24.34 | 2025 | Besremi |
| Regeneron Healthcare Solutions, INC. | $18.54 | 2024 | Libtayo |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $17.00 | 2025 | Tevimbra |
| Ibsa Pharma INC. | $16.70 | 2024 | Flector, Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omayra Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.